PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure  **Companies to host conference call Monday, December 1, 2008 at 8:30 a.m. ET to discuss results
View HTML
Toggle Summary Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
New Findings Published in the Journal Cancer Cell Highlight Role of miR-296 in Regulating Pathways of Angiogenesis and Demonstrate Potential New Applications of microRNA Therapeutics in Cancer
View HTML
Toggle Summary Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
Allowances by U.S. Patent Office Enhance the “Crooke” Patent Estate by Adding Broad Claims That Cover RNA-Based Product Compositions and Methods of Treatment Expands Intellectual Property Position of Alnylam for RNAi Therapeutics and Regulus for microRNA Therapeutics
View HTML
Toggle Summary Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Appointment of Industry Renowned Leader Adds Extensive Experience to Board
View HTML
Toggle Summary Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance CAMBRIDGE, Mass. and CARLSBAD, Calif., August 4, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc.
View HTML
Toggle Summary Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies CAMBRIDGE, Mass. and CARLSBAD, Calif., June 24, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University CAMBRIDGE, Mass. and CARLSBAD, Calif., May 6, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop microRNA Targeted Therapeutics to Treat Inflammatory Diseases
Companies Announce Significant microRNA Therapeutics Collaboration
View HTML
Toggle Summary Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer CAMBRIDGE, Mass. and CARLSBAD, Calif., February 11, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML